Investor Alert

Market Pulse Archives

Aug. 14, 2020, 6:42 a.m. EDT

CureVac raises $213.3 million in IPO after pricing at $16 a share, high end of proposed range

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Ciara Linnane

CureVac BV, a clinical-stage biotech headquartered in Germany, priced its initial public offering on Friday at $16 a share, the high end of its proposed range. The company sold 13.3 million shares to raise $213.3 million. The stock will start trading on Nasdaq later Friday under the ticker "CVAC." BofA Securities, Jefferies, Credit Suisse after joint bookrunners on the deal, with Berenber and Kempen & Co. acting as co-managers. Proceeds will be used to fund clinical research, R&D, to expand manufacturing facilities and for general corporate purposes. "We are a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people," the company says in its prospectus. "Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs."

Get news alerts on CureVac N.V. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.